The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
Open accessAbstract
BACKGROUND: Patients infected with HIV-1 initiating antiretroviral therapy (ART) containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) show presumably fewer atherogenic lipid changes than those initiating most ARTs containing a protease inhibitor. We analysed whether lipid changes differed between the two most commonly used NNRTIs, nevirapine (NVP) and efavirenz (EFV). METHODS AND FINDINGS: Prospective analysis of lipids and lipoproteins was performed in patients enrolled in the NVP and EFV treatment groups of the 2NN study who remained on allocated treatment during 48 wk of follow-up. Patients were allocated to NVP (n = 417), or EFV (n = 289) in combination with stavudine and lamivudine. The primary endpoint was percentage change over 48 wk in high-density lipoprotein cholesterol (HDL-c), total cholesterol (TC), TC:HDL-c ratio, non-HDL-c, low-density lipoprotein cholesterol, and triglycerides. The increase of HDL-c was significantly larger for patients receiving NVP (42.5%) than for patients receiving EFV (33.7%; p = 0.036), while the increase in TC was lower (26.9% and 31.1%, respectively; p = 0.073), resulting in a decrease of the TC:HDL-c ratio for patients receiving NVP (-4.1%) and an increase for patients receiving EFV (+5.9%; p < 0.001). The increase of non-HDL-c was smaller for patients receiving NVP (24.7%) than for patients receiving EFV (33.6%; p = 0.007), as were the increases of triglycerides (20.1% and 49.0%, respectively; p < 0.001) and low-density lipoprotein cholesterol (35.0% and 40.0%, respectively; p = 0.378). These differences remained, or even increased, after adjusting for changes in HIV-1 RNA and CD4+ cell levels, indicating an effect of the drugs on lipids over and above that which may be explained by suppression of HIV-1 infection. The increases in HDL-c were of the same order of magnitude as those seen with the use of the investigational HDL-c-increasing drugs. CONCLUSION: NVP-containing ART shows larger increases in HDL-c and decreases in TC:HDL-c ratio than an EFV-containing regimen. Based on these findings, protease-inhibitor-sparing regimens based on non-nucleoside reverse transcriptase inhibitor, particularly those containing NVP, may be expected to result in a reduced risk of coronary heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Antihyperlipidemic and Biochemical Activities of Mcy Protein in Streptozotocin Induced Diabetic Rats
Marella, S., Maddirela, D. R., Badri, K. R., Jyothi Kumar, M. V., & Chippada, A. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373954 · Cited by 5,938
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Nissen, S. E., Tsunoda, T., Tuzcu, E. M., Schoenhagen, P., Cooper, C. J., Yasin, M., Eaton, G. M., Lauer, M. A., Sheldon, W. S., Grines, C. L., et al. (2003) · JAMA · doi:10.1001/jama.290.17.2292 · Cited by 1,707
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,495
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
Self-citationLipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen, V. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410050061031 · Cited by 957
Grunfeld, C. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.1045 · Cited by 848
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Endothelial Function: A Barometer for Cardiovascular Risk?
Vita, J. A., & Keaney, J. F. (2002) · Circulation · doi:10.1161/01.cir.0000028581.07992.56 · Cited by 737
van Leth, F., Phanuphak, P., Ruxrungtham, K., Baraldi, E., Miller, S., Gazzard, B., Cahn, P., Lalloo, U., van der Westhuizen, I., Malan, D., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)15997-7 · Cited by 684
Self-citationCarr, A., Miller, J., Law, M., & Cooper, D. A. (2000) · AIDS · doi:10.1097/00002030-200002180-00001 · Cited by 630
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 625
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624
Intima–media thickness: a new tool for diagnosis and treatment of cardiovascular risk
Simon, A., Gariepy, J., Chironi, G., Megnien, J.-L., & Levenson, J. (2002) · Journal of Hypertension · doi:10.1097/00004872-200202000-00001 · Cited by 613
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J.-J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., Nicod, P., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 605
Mary-Krause, M., Cotte, L., Simon, A., Partisani, M., & Costagliola, D. (2003) · AIDS · doi:10.1097/00002030-200311210-00010 · Cited by 564
Coronary Heart Disease in HIV-Infected Individuals
Currier, J. S., Taylor, A., Boyd, F., Dezii, C. M., Kawabata, H., Burtcel, B., Maa, J.-F., & Hodder, S. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200308010-00012 · Cited by 537
Behrens, G., Dejam, A., Schmidt, H., Balks, H.-J., Brabant, G., Körner, T., Stoll, M., & Schmidt, R. E. (1999) · AIDS · doi:10.1097/00002030-199907090-00001 · Cited by 515
Protease inhibitors and cardiovascular outcomes in patients with HIV-1
Holmberg, S. D., Moorman, A. C., Williamson, J. M., Tong, T. C., Ward, D. J., Wood, K. C., Greenberg, A. E., & Janssen, R. S. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11672-2 · Cited by 488
Stein, J. H., Klein, M. A., Bellehumeur, J. L., McBride, P. E., Wiebe, D. A., Otvos, J. D., & Sosman, J. M. (2001) · Circulation · doi:10.1161/01.cir.104.3.257 · Cited by 479
Klein, D., Hurley, L. B., Quesenberry, C. P., & Sidney, S. (2002) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200208150-00002 · Cited by 420
Saves, M., Chene, G., Ducimetiere, P., Leport, C., Le Moal, G., Amouyel, P., Arveiler, D., Ruidavets, J.-B., Reynes, J., Bingham, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375844 · Cited by 400
Self-citationFontas, E., van Leth, F., Sabin, C. A., Friis‐Møller, N., Rickenbach, M., d’Arminio Monforte, A., Kirk, O., Dupon, M., Morfeldt, L., Mateu, S., et al. (2004) · The Journal of Infectious Diseases · doi:10.1086/381783 · Cited by 337
Self-citationReversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
Martínez, E., Conget, I., Lozano, L., Casamitjana, R., & Gatell, J. M. (1999) · AIDS · doi:10.1097/00002030-199905070-00009 · Cited by 321
Bisoendial, R. J., Hovingh, G. K., Levels, J. H. M., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J. P., & Stroes, E. S. G. (2003) · Circulation · doi:10.1161/01.cir.0000070934.69310.1a · Cited by 288
Self-citationPremature atherosclerosis in HIV-infected individuals – focus on protease inhibitor therapy
Depairon, M., Chessex, S., Sudre, P., Rodondi, N., Doser, N., Chave, J.-P., Riesen, W., Nicod, P., Darioli, R., Telenti, A., et al. (2001) · AIDS · doi:10.1097/00002030-200102160-00005 · Cited by 273
van der Valk, M., Kastelein, J. J. P., Murphy, R. L., van Leth, F., Katlama, C., Horban, A., Glesby, M., Behrens, G., Clotet, B., Stellato, R. K., et al. (2001) · AIDS · doi:10.1097/00002030-200112070-00008 · Cited by 253
Self-citationHeath, K. V., Hogg, R. S., Chan, K. J., Harris, M., Montessori, V., O'Shaughnessy, M. V., & Montaner, J. S. G. (2001) · AIDS · doi:10.1097/00002030-200101260-00013 · Cited by 249
Sanne, I., Piliero, P., Squires, K., Thiry, A., & Schnittman, S. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200301010-00004 · Cited by 226
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00022-1 · Cited by 207
Influence of Low HDL on Progression of Coronary Artery Disease and Response to Fluvastatin Therapy
Ballantyne, C. M., Herd, J. A., Ferlic, L. L., Dunn, J. K., Farmer, J. A., Jones, P. H., Schein, J. R., & Gotto, A. M. (1999) · Circulation · doi:10.1161/01.cir.99.6.736 · Cited by 198
Murphy, R. L., Sanne, I., Cahn, P., Phanuphak, P., Percival, L., Kelleher, T., & Giordano, M. (2003) · AIDS · doi:10.1097/00002030-200312050-00007 · Cited by 195
Self-citationDressman, J., Kincer, J., Matveev, S. V., Guo, L., Greenberg, R. N., Guerin, T., Meade, D., Li, X.-A., Zhu, W., Uittenbogaard, A., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16261 · Cited by 172
Negredo, E., Cruz, L., Paredes, R., Ruiz, L., Fumaz, C. R., Bonjoch, A., Gel, S., Tuldrà, A., Balagué, M., Johnston, S. S., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/324629 · Cited by 170
Mercié, P., Thiébaut, R., Aurillac-Lavignolle, V., Pellegrin, J., Yvorra-Vives, M. C., Morlat, P., Ragnaud, J., Dupon, M., Malvy, D. J.-M., Bellet, H., et al. (2002) · Annals of Medicine · doi:10.1080/078538902317338652 · Cited by 140
Brewer, H. B. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000121505.88326.d2 · Cited by 128
Seminari, E. M., Pan, A., Voltini, G., Carnevale, G., Maserati, R., Minoli, L., Meneghetti, G., Tinelli, C., & Testa, S. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00736-5 · Cited by 127
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
Calza, L., Manfredi, R., & Chiodo, F. (2003) · AIDS · doi:10.1097/00002030-200304110-00010 · Cited by 120
Gotto, A. M. (2001) · Circulation · doi:10.1161/01.cir.103.17.2213 · Cited by 114
Asztalos, B. F., Horvath, K. V., McNamara, J. R., Roheim, P. S., Rubinstein, J. J., & Schaefer, E. J. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(02)00149-1 · Cited by 109
Miller, J., Brown, D., Amin, J., Kent-Hughes, J., Law, M. G., Kaldor, J. M., Cooper, D. A., & Carr, A. D. (2002) · AIDS · doi:10.1097/00002030-200211080-00012 · Cited by 96
Carotid Intima-Media Thickness in Heavily Pretreated HIV-Infected Patients
Chironi, G. N., Escaut, L., Gariépy, J., Cogny, A., Monsuez, J.-J., Levenson, J. A., Simon, A. C., & Vittecoq, D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200304150-00004 · Cited by 67
Núñez, M., Soriano, V., Martín‐Carbonero, L., Barrios, A., Barreiro, P., Blanco, F., García-Benayas, T., & González‐Lahoz, J. (2002) · HIV Clinical Trials · doi:10.1310/0cj5-2abq-cb00-6mr6 · Cited by 66
Body Habitus Changes Related to Lipodystrophy
Sattler, F. R. (2003) · Clinical Infectious Diseases · doi:10.1086/367563 · Cited by 43
Bonnet, F., Balestre, É., Thiébaut, R., Mercié, P., Dupon, M., Morlat, P., Dabis, F., & (GECSA), F. T. G. D. C. D. S. E. A. (2004) · HIV Medicine · doi:10.1111/j.1468-1293.2004.00200.x · Cited by 38
Penzak, S. R., & Chuck, S. K. (2002) · Expert Opinion on Drug Safety · doi:10.1517/14740338.1.1.5 · Cited by 28
Cited by
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521
Treatment for Adult HIV Infection: 2006 Recommendations of the International AIDS Society–USA Panel
Hammer, S. M., Saag, M. S., Schechter, M., Montaner, J. S. G., Schooley, R. T., Jacobsen, D. M., Thompson, M. A., Carpenter, C. C. J., Fischl, M. A., Gazzard, B. G., et al. (2006) · JAMA · doi:10.1001/jama.296.7.827 · Cited by 1,033
Self-citationWorm, S. W., Sabin, C., Weber, R., Reiss, P., El‐Sadr, W., Dabis, F., De Wit, S., Law, M., Monforte, A. D., Friis‐Møller, N., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/649897 · Cited by 648
Self-citationLang, S. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.197 · Cited by 306
Metadata
- Authors
- van Leth, F., Phanuphak, P., Stroes, E., Gazzard, B., Cahn, P., Raffi, F., Wood, R., Bloch, M., Katlama, C., Kastelein, J. J. P., Schechter, M., Murphy, R. L., Horban, A., Hall, D. B., Lange, J. M. A., & Reiss, P.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2004-10-19
- Volume
- 1
- Issue
- 1
- Pages
- e19
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2156188065
- Cited by
- 276
- References
- 54
- FWCI
- 20.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.